SEC Tracker
Get the app

Glycomimetics CBIO

Glycomimetics FY 2024: net loss $37.9M; diluted EPS −$59.00

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Glycomimetics reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$37.9MAgainst −$36.9M in FY 202310-K income statement, on EDGAR
  2. Diluted EPS−$59.00Against −$58.00 in FY 2023. Split-adjusted, as the tables show it; the filing reported −$0.5910-K income statement, on EDGAR
  3. Cash and cash equivalents$10.7M−74% from $41.8M in FY 202310-K balance sheet, on EDGAR
  4. Cash from operations−$31.1MAgainst −$34.9M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Glycomimetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Omeros OMER public float $172M, Jun 30, 2025
  2. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  3. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. Editas Medicine EDIT public float $191M, Jun 30, 2025